News Briefing channel feed – Endpoints News

News Briefing channel feed

Novartis reportedly in talks to buy MorphoSys; Astellas cuts PhII program; Silence's $120M private placement

Last year

Hutchmed's licensing deal, worth up to $227M; Tyra's $200 PIPE

Last year

Basking raises $55M; Seroba’s fourth fund; Vera upsizes its public offering

Last year

Halia's $30M Series C; Windtree assesses 'strategic' options; LifeArc, Gates invest in Africa accelerator

Last year

Kura’s stock jumps on PhIb readout; FDA lifts hold on INmune Bio program; Nanobiotix’s $20M milestone

Last year

Ascendis spins out ophthalmology company; Gamida Cell eyes strategic options

Last year

Deerfield gives up rights to Windtree therapy; Travere inks deal with Renalys in Asia; Celularity raises $21M

Last year

Glenmark, Alphamab deal worth up to $700M; Tourmaline’s $150M offering; Repare records $40M milestone

Last year

Kura’s $150M PIPE; Lilly’s investment in Prism BioLab; Annovis delays PhIII data, citing ‘data cleaning’

Last year

Merck inks deal with Unnatural Products; CG Oncology’s upsized IPO; Locus gets $24M from BARDA

Last year

Sagimet’s positive PhIIb NASH data; FDA lifts hold on Pharvaris IND; Dianthus raises $230M

Last year

PMV to cut 30% of its workforce; Edgewise, Esperion announce public offerings

Last year

Viridian’s $150M offering; Surrozen scraps IBD drug candidate; Assembly ends deal with Indiana University

Last year

Lee’s Pharma to develop Windtree drug in China; Acurx shares PhIIb antibiotic data; Granata raises $14M

Last year

Doudna’s new venture; Aclaris CEO to step down; Tome’s $114M liver disorder deal with Genevant

Last year

Ji Xing buys Biogen’s acute ischemic stroke drug; Exelixis/BioInvent partnership ends; ClinChoice's deal in SEA

Last year

Dermavant's PhIII eczema data; Oxford's Nipah vaccine; Inventiva's €25M lifeline

Last year

Aclaris' mixed PhIIb eczema data; Amgen licenses Xeris' tech; Bolden Tx secures funding

Last year

TG licenses Precision's cell therapy; Innovent's PhIII weight loss win; Atea's positive hep C data

Last year

Senti Bio cuts 37% of staff; Evotec pockets $25M milestone from BMS; Novartis buys SanReno

Last year

Boehringer’s deal spree; Praxis’ licensing pact with Shanghai biotech; Vico Therapeutics raises $60M

Last year

Rhythm licenses obesity drug for $100M; Galapagos teams up with BridGene; Insilico’s new deal

Last year

J&J’s new partnership with Elektrofi; Enyo raises €39M; Arrowhead's $450M offering

Last year

AstraZeneca's $40M deal with Allorion; Apollo raises $33M; Xoma's stock buyback

Last year

First page Previous page 10 11 121314 15 16 Next page Last page